Myburgh D P, Goldman a P, Cartoon J, Schamroth J M
S Afr Med J. 1979 Aug 25;56(8):295-8.
Sotalol (Sotacor) is a beta-adrenergic receptor blocking agent, which in addition possesses class III anti-arrhythmic properties. In this study we report on the clinical effectiveness of sotalol in the suppression of ventricular ectopic beats in 20 patients suffering from ischaemic heart disease. Sotalol was compared with placebo and efficacy was determined by Holter tape monitoring. Sotalol produced an 88,5% (P < 0,001) reduction in ectopic beat frequency at the optimal titrated dosage, with relatively few physical or biochemical side-effects. In situations where ventricular anti-arrhythmic therapy is deemed necessary, especially if long-term use is considered, sotalol seems to be the agent of choice.
索他洛尔(施太可)是一种β肾上腺素能受体阻滞剂,此外还具有Ⅲ类抗心律失常特性。在本研究中,我们报告了索他洛尔对20例缺血性心脏病患者室性早搏的临床疗效。将索他洛尔与安慰剂进行比较,并通过动态心电图监测来确定疗效。在最佳滴定剂量下,索他洛尔可使早搏频率降低88.5%(P<0.001),且身体或生化方面的副作用相对较少。在认为有必要进行室性抗心律失常治疗的情况下,特别是考虑长期使用时,索他洛尔似乎是首选药物。